Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Delphinidin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.97 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.97 |
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.69 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.67 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.97 |
| ▸ | SNCA | P37840 | 3/20 | 0.97 |
| ▸ | EP300 | Q09472 | 2/20 | 0.97 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.97 |
| ▸ | CD38 | P28907 | 11/20 | 0.93 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.69 |
| ▸ | F2 | P00734 | 1/20 | 0.67 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.67 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delphinidin SCHEMBL29692969 | 0.98 | GLO1 (1.00) | GLO1SNCAEGFRKDREP300 | |
| Delphinidin SCHEMBL22369 | 0.98 | GLO1 (1.00) | GLO1SNCAEGFRKDREP300 | |
| Delphinidin SCHEMBL22370 | 0.97 | CD38 (1.00) | GLO1SNCAEGFRKDREP300 | |
| Delphinidin SCHEMBL9063189 | 0.90 | CD38 (0.86) | GLO1SNCAEGFRKDREP300 | |
| Petunidin SCHEMBL8411777 | 0.87 | CD38 (0.95) | GLO1SNCAEGFRKDREP300 | |
| Petunidin SCHEMBL9120043 | 0.87 | CD38 (0.95) | GLO1SNCAEGFRKDREP300 | |
| Petunidin SCHEMBL21649 | 0.85 | CD38 (0.97) | GLO1SNCAEGFRKDREP300 | |
| Petunidin SCHEMBL30683343 | 0.85 | CD38 (0.97) | GLO1SNCAEGFRKDREP300 | |
| Petunidin SCHEMBL29947229 | 0.85 | CD38 (0.97) | GLO1SNCAEGFRKDREP300 | |
| Cyanidin SCHEMBL7931530 | 0.84 | GLO1 (0.97) | GLO1SNCAEGFRKDREP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630776-B2 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2026-05-19 | — | — | US | claimed |
| US-20240417636-A1 | FUEL ADDITIVE COMPOSITION | TAYLOR CLIFTON RAY (US) | 2024-12-19 | — | — | US | claimed |
| CN-118914413-A | Ultra-high performance liquid chromatography-tandem mass spectrometry method for simultaneously detecting 39 kinds of anthocyanin in litchi | 海南省农业科学院三亚研究院(海南省实验动物研究中心) | 2024-11-08 | — | — | CN | claimed |
| US-12091623-B2 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2024-09-17 | — | — | US | claimed |
| US-20240110114-A1 | FUEL ADDITIVE COMPOSITION | TAYLOR CLIFTON RAY (US) | 2024-04-04 | — | — | US | claimed |
| US-11807824-B1 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2023-11-07 | — | — | US | claimed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | claimed |
| CN-115963195-A | Anthocyanin detection method | 中国科学院华南植物园 | 2023-04-14 | — | — | CN | claimed |
| WO-2021194396-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | OBSHCHESTVO S OGRANICHENNOY OTVESTVENNOSTYU "GERO" (RU) | 2021-09-30 | — | — | WO | claimed |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-03 | — | — | US | claimed |
| EP-2670404-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | The Trustees of Princeton University (US) | 2013-12-11 | — | — | EP | claimed |
| US-20130252236-A1 | TUMOR STEM CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-09-26 | — | — | US | claimed |
| WO-2012106509-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-09 | — | — | WO | claimed |
| US-20110293525-A1 | TUMOR STEM CELLS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-12-01 | — | — | US | claimed |
| CN-101482500-B | Fast detection method for dihydro flavanol 4-reductase/leucocyanidin reductase in tree plant | UNIV ANHUI AGRICULTURE | 2010-08-18 | — | — | CN | claimed |
| CN-101482500-A | Fast detection method for dihydro flavanol 4-reductase/leucocyanidin reductase in tree plant | UNIV ANHUI AGRICULTURE (CN) | 2009-07-15 | — | — | CN | claimed |
| US-6159585-A | Security paper | GEORGIA-PACIFIC CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| WO-1998041688-A1 | SECURITY PAPER | GEORGIA-PACIFIC CORPORATION, INC. (US) | 1998-09-24 | — | — | WO | claimed |
| JP-3209321-A | — | — | None | — | — | JP | disclosed |
| JP-2289562-A | — | — | None | — | — | JP | disclosed |
| US-12630776-B2 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630776-B2 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2026-05-19 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250367167-A1 | COMPOSITION FOR MITOCHONDRIAL MODIFICATION COMPRISING A COMBINATION OF TWO OR MORE NATURAL PIGMENTS | UNIVERSITY OF SEOUL INDUSTRY COOPERATION FOUNDATION (KR) | 2025-12-04 | — | — | US | disclosed |
| US-20250360368-A1 | GOLF BALL HAVING COLOR-SHIFT EFFECT | ACUSHNET COMPANY (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250332482-A1 | GOLF BALLS HAVING CHROMOGENIC POLYMERS IN ONE OR MORE LAYERS | ACUSHNET COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025175697-A1 | DIFFERENTIATION-INDUCING CULTURE MEDIUM FOR TRANSFORMATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS INTO CHONDROCYTES, AND USE THEREOF | 广东先康达生物科技有限公司 | 2025-08-28 | — | — | WO | disclosed |
| US-12383798-B2 | Golf balls having chromogenic polymers in one or more layers | ACUSHNET COMPANY (US) | 2025-08-12 | — | — | US | disclosed |
| US-12383799-B2 | Golf balls having unique effect pigments in one or more layers | ACUSHNET COMPANY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4592401-A2 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | Bruker Spatial Biology, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4214331-B1 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | BRUKER SPATIAL BIOLOGY INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250090290-A1 | INTRAORAL COLORIMETRIC SENSORS FOR PATIENT MONITORING | ALIGN TECHNOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240424010-A1 | NICOTINAMIDE RIBOSIDE TRIOLEATES CHLORIDE, COMPOSITIONS CONTAINING THIS COMPOUND, AND METHODS OF MAKING AND USING THIS COMPOUND | NESTLE SA (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240417636-A1 | FUEL ADDITIVE COMPOSITION | TAYLOR CLIFTON RAY (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240417636-A1 | FUEL ADDITIVE COMPOSITION | TAYLOR CLIFTON RAY (US) | 2024-12-19 | — | — | US | disclosed |
| CN-118914413-B | Ultra-high performance liquid chromatography-tandem mass spectrometry method for simultaneously detecting 39 kinds of anthocyanin in litchi | 海南省农业科学院三亚研究院(海南省实验动物研究中心) | 2024-12-03 | — | — | CN | disclosed |
| WO-2024233683-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | ALUME BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118914413-A | Ultra-high performance liquid chromatography-tandem mass spectrometry method for simultaneously detecting 39 kinds of anthocyanin in litchi | 海南省农业科学院三亚研究院(海南省实验动物研究中心) | 2024-11-08 | — | — | CN | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| CN-115612699-B | Copolymer membrane, and enzymatic self-assembly synthesis method and application thereof in gas-liquid interface | 中国科学院天津工业生物技术研究所 | 2024-10-25 | — | — | CN | disclosed |
| CN-118804688-A | For improving associated menstruation composition for discomfortable state | 日本乐敦制药株式会社 | 2024-10-18 | — | — | CN | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12091623-B2 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2024-09-17 | — | — | US | disclosed |
| US-12091623-B2 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2024-09-17 | — | — | US | disclosed |
| CN-118615267-A | New use of small molecule medicine in inhibiting coronavirus | 成都融昶生物科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4408192-A1 | NICOTINAMIDE RIBOSIDE TRIOLEATES CHLORIDE, COMPOSITIONS CONTAINING THIS COMPOUND, AND METHODS OF MAKING AND USING THIS COMPOUND | Société des Produits Nestlé S.A. (CH) | 2024-08-07 | — | — | EP | disclosed |
| CN-118383366-A | Antibacterial composition for preventing and treating gray mold of tomatoes and application thereof | 贵州大学 | 2024-07-26 | — | — | CN | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240198182-A1 | GOLF BALLS HAVING CHROMOGENIC POLYMERS IN ONE OR MORE LAYERS | JPMORGAN CHASE BANK, N.A. | 2024-06-20 | — | — | US | disclosed |
| US-20240198183-A1 | GOLF BALLS HAVING UNIQUE EFFECT PIGMENTS IN ONE OR MORE LAYERS | JPMORGAN CHASE BANK, N.A. | 2024-06-20 | — | — | US | disclosed |
| CN-118139532-A | Nicotinamide riboside trioleate chlorides, compositions containing such compounds, and methods of making and using such compounds | 雀巢产品有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117736980-B | Induced differentiation medium for transforming adipose-derived mesenchymal stem cells into chondrocytes and application thereof | 广东先康达生物科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117736980-B | Induced differentiation medium for transforming adipose-derived mesenchymal stem cells into chondrocytes and application thereof | 广东先康达生物科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20240124523-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-18 | — | — | US | disclosed |
| US-20240110114-A1 | FUEL ADDITIVE COMPOSITION | TAYLOR CLIFTON RAY (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240110114-A1 | FUEL ADDITIVE COMPOSITION | TAYLOR CLIFTON RAY (US) | 2024-04-04 | — | — | US | disclosed |
| CN-117736980-A | Induced differentiation medium for transforming adipose-derived mesenchymal stem cells into chondrocytes and application thereof | 广东先康达生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117736980-A | Induced differentiation medium for transforming adipose-derived mesenchymal stem cells into chondrocytes and application thereof | 广东先康达生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| CN-117589540-A | Blueberry freeze-dried powder standard substance containing six anthocyanidins and preparation method and application thereof | 郑少锋 | 2024-02-23 | — | — | CN | disclosed |
| US-20240058408-A1 | COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION CONTAINING GINSENG BERRY EXTRACT | HOLISTIC BIO CO., LTD. (KR) | 2024-02-22 | — | — | US | disclosed |
| CN-115612114-B | Copolymer membrane and method for enzymatic self-assembly synthesis and application thereof | 中国科学院天津工业生物技术研究所 | 2024-02-20 | — | — | CN | disclosed |
| US-20240016821-A1 | DRINK PRODUCT AND USE THEREOF | HYGIA PHARMACEUTICALS, LLC | 2024-01-18 | — | — | US | disclosed |
| CN-115612403-B | Self-assembled strong-adhesion copolymer film, coating method and application | 中国科学院天津工业生物技术研究所 | 2023-12-01 | — | — | CN | disclosed |
| CN-117120629-A | Chemical compositions and methods of use thereof | 纳米线科技公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230366012-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | BRUKER SPATIAL BIOLOGY, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11807824-B1 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807824-B1 | Fuel additive composition | TAYLOR CLIFTON RAY (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116999396-A | Modular compositions for removal of soluble biomolecules and related methods | 纳米提克斯有限责任公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11802138-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-31 | — | — | US | disclosed |
| CN-116785457-A | Compositions and methods related to particle removal | 纳米提克斯有限责任公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116763941-A | Compositions and methods related to particle removal | 纳米提克斯有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| US-11761040-B2 | DNA protection agent in DNA imaging buffer | MGI TECH CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-11744820-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11730747-B2 | Drink product and use thereof | HYGIA PHARMACEUTICALS, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4214331-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | Nanostring Technologies, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | disclosed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| CN-115990272-A | Compositions and methods for inhibiting biological activity of soluble biomolecules | 纳米提克斯有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115963195-A | Anthocyanin detection method | 中国科学院华南植物园 | 2023-04-14 | — | — | CN | disclosed |
| WO-2023052573-A1 | NICOTINAMIDE RIBOSIDE TRIOLEATES CHLORIDE, COMPOSITIONS CONTAINING THIS COMPOUND, AND METHODS OF MAKING AND USING THIS COMPOUND | Société des Produits Nestlé S.A. (CH) | 2023-04-06 | — | — | WO | disclosed |
| US-20230033699-A1 | DNA PROTECTION AGENT IN DNA IMAGING BUFFER | MGI TECH CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| WO-2023286950-A1 | COMPOSITION CONTAINING GINSENG BERRY EXTRACT AND LUTEIN FOR PREVENTING OR TREATING MACULAR DEGENERATION | 주식회사 홀리스틱바이오 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284777-A1 | COPOLYMER FILM, ENZYME CATALYSIS SELF-ASSEMBLY SYNTHESIS METHOD THEREFOR, AND APPLICATION THEREOF | 中国科学院天津工业生物技术研究所 | 2023-01-19 | — | — | WO | disclosed |
| CN-115612699-A | Copolymer membrane and enzymatic self-assembly synthesis method and application thereof at gas-liquid interface | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-115612403-A | Self-assembly strong-adhesion copolymer film, film coating method and application | 中国科学院天津工业生物技术研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-115500510-A | Blueberry extract capsule and preparation method thereof | 上海科源顺兴生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4041311-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | Alume Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022145813-A1 | COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION CONTAINING GINSENG BERRY EXTRACT | 주식회사 홀리스틱바이오 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2022060967-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | NANOSTRING TECHNOLOGIES, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022050431-A1 | PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTION OR TREATMENT OF OSTEOARTHRITIS | 경상국립대학교병원 | 2022-03-10 | — | — | WO | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-3922702-A1 | PROCESS FOR OBTAINING EXTRACTS OF CONDENSED TANNINS FROM AERIAL PART OF CISTUS LADANIFER L | Cebal - Centro De Biotecnologia Agrícola E Agro-Alimentar Do Alentejo (PT) | 2021-12-15 | — | — | EP | disclosed |
| CN-113750085-A | Application of natural compound and derivative thereof in treating arterial lesion | 中国科学院上海药物研究所 | 2021-12-07 | — | — | CN | disclosed |
| US-20210369745-A1 | DRINK PRODUCT AND USE THEREOF | HYGIA PHARMACEUTICALS, LLC | 2021-12-02 | — | — | US | disclosed |
| CN-105358168-B | Composition having function of relieving premenstrual syndrome and dysmenorrhea | 株式会社爱茉莉太平洋 | 2021-11-30 | — | — | CN | disclosed |
| US-20210363186-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2021-11-18 | — | — | US | disclosed |
| WO-2021213321-A1 | DNA PROTECTION AGENT IN DNA IMAGING BUFFER | MGI TECH CO., LTD. (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-11147792-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| WO-2021194396-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | OBSHCHESTVO S OGRANICHENNOY OTVESTVENNOSTYU "GERO" (RU) | 2021-09-30 | — | — | WO | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210275550-A1 | DRINK PRODUCT CONTAINING GENISTEIN AND USE THEREOF | HYGIA PHARMACEUTICALS, LLC | 2021-09-09 | — | — | US | disclosed |
| CN-113244404-A | Beverage and its use | 海加制药有限责任公司 | 2021-08-13 | — | — | CN | disclosed |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| US-11045465-B2 | Methods and compositions to prevent addiction | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11021517-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| CN-108918711-B | Detection method of polyphenol compounds in tobacco leaves | 中国烟草总公司郑州烟草研究院 | 2021-05-18 | — | — | CN | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| WO-2021072289-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210087229-A1 | Optimized Peptides for Targeting Human Nerves and Their Use in Image Guided Surgery, Diagnostics and Therapeutic Delivery | UNIV CALIFORNIA (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210047441-A1 | ANTHOCYANIDIN COMPLEX | SAPIOTEC GMBH (DE) | 2021-02-18 | — | — | US | disclosed |
| US-20210030713-A1 | ANTHOCYANIDIN COMPLEX | SAPIOTECH GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
| EP-3768095-A2 | COMPOSITIONS AND METHODS FOR TREATING DIARRHEAL DISEASES | Vanessa Research, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20210008028-A1 | COMPOSITIONS AND METHODS FOR TREATING DIARRHEAL DISEASES | VANESSA RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-111944071-A | Preparation method of antineoplastic drug microcapsule | 嘉兴市爵拓科技有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3730507-A1 | NICOTINOYL RIBOSIDE AND NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR USE IN REDUCING TOXICITY INDUCED BY HMG-COA REDUCTASE INHIBITORS | Cornell Research Foundation, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| CN-111759828-A | Composition and application thereof in treating and/or preventing dementia | 许悦郎 | 2020-10-13 | — | — | CN | disclosed |
| US-20200306252-A1 | COMPOSITION FOR PREVENTING AND/OR TREATING DEMENTIA | SHEU ERIC YUEH LANG (TW) | 2020-10-01 | — | — | US | disclosed |
| US-20200289535-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200239522-A1 | Optimized Peptides for Targeting Human Nerves and Their Use in Image Guided Surgery, Diagnostics and Therapeutic Delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-20200181632-A1 | METHODS FOR ENGINEERING PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING MYB TRANSCRIPTION FACTORS | UNIVERSITY OF NORTH TEXAS (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3661539-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of The University of California (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10668096-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200163933-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3624782-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | Axial Biotherapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10596259-B2 | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-24 | — | — | US | disclosed |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200046843-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-10-10 | — | — | US | disclosed |
| US-20190298799-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. | 2019-10-03 | — | — | US | disclosed |
| WO-2019180688-A2 | COMPOSITIONS AND METHODS FOR TREATING DIARRHEAL DISEASES | VANESSA RESEARCH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-10385380-B2 | Personalized protease assay to measure protease activity in neoplasms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| CN-110051844-A | Drink and its purposes | 海加制药有限责任公司 | 2019-07-26 | — | — | CN | disclosed |
| US-10342836-B2 | Composition having a function for alleviating premenstrual syndrome and menstrual pain | AMOREPACIFIC CORPORATION (KR) | 2019-07-09 | — | — | US | disclosed |
| US-20190192542-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| EP-2525831-B1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA AS (DK) | 2019-05-15 | — | — | EP | disclosed |
| EP-3478269-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | Otonomy, Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| CN-109689027-A | Triglycerides aural preparations and application thereof | 奥德纳米有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-106442787-B | The foundation of liquid chromatogram retention index and its application in terms of compound characterization | 中国烟草总公司郑州烟草研究院 | 2019-04-12 | — | — | CN | disclosed |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
| WO-2019028281-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2997029-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| WO-2018213204-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20180298115-A1 | ANTHOCYANIDIN COMPLEX | SAPIOTEC GMBH (DE) | 2018-10-18 | — | — | US | disclosed |
| CN-106029789-B | Anthocyanidin compound | 赛博尔泰克股份公司 | 2018-10-12 | — | — | CN | disclosed |
| US-10092580-B2 | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| EP-3369738-A1 | NICOTINYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | Cornell Research Foundation, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2670404-B1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | UNIV PRINCETON (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2018136476-A1 | METHODS FOR ENGINEERING PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING MYB TRANSCRIPTION FACTORS | UNIVERSITY OF NORTH TEXAS (US) | 2018-07-26 | — | — | WO | disclosed |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180140703-A1 | TUMOR RADIOSENSITIZATION WITH ANTIBODY CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-24 | — | — | US | disclosed |
| US-9957271-B2 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9949947-B2 | Delphinidin for combating melanoma cells | SAPIOTEC GMBH (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9925274-B2 | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient | SAPIOTEC GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
| WO-2018005830-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9808532-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170305968-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| EP-3221312-A2 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3220918-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-27 | — | — | EP | disclosed |
| EP-3221316-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-27 | — | — | EP | disclosed |
| EP-3221322-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-27 | — | — | EP | disclosed |
| EP-3221317-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-27 | — | — | EP | disclosed |
| CN-107207509-A | Substituted bridged ring urea analogs as sirtuin modulators | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-107207496-A | Substituted bridged ring urea analogs as sirtuin modulators | 葛兰素史密斯克莱有限责任公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-104302673-B | Anthocyanidin compound | 赛博尔泰克股份公司 | 2017-09-22 | — | — | CN | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170175084-A1 | TUMOR STEM CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-06-22 | — | — | US | disclosed |
| US-9682151-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170122954-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-3152220-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-12 | — | — | EP | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| US-20170080088-A1 | TUMOR RADIOSENSITIZATION WITH MONOMETHYL AURISTATIN E (MMAE) AND DERIVATIVES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| CN-104302183-B | Use of delphinidin against staphylococcus aureus | 赛博尔泰克股份公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106442787-A | Establishment of liquid chromatographic retention index and application of establishment to compound qualitative aspect | 中国烟草总公司郑州烟草研究院 | 2017-02-22 | — | — | CN | disclosed |
| US-9561285-B2 | Carrier-linked carbamate prodrug linkers | ASCENDIS PHARMA AS (DK) | 2017-02-07 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170014377-A1 | ANTHOCYANIDIN COMPLEX | SAPIOTEC GMBH (DE) | 2017-01-19 | — | — | US | disclosed |
| US-20160367614-A1 | COMPOSITION HAVING A FUNCTION FOR ALLEVIATING PREMENSTRUAL SYNDROME AND MENSTRUAL PAIN | AMOREPACIFIC CORPORATION (KR) | 2016-12-22 | — | — | US | disclosed |
| US-9511047-B2 | Delphinidin for combating melanoma cells | SAPIOTEC GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| CN-102083438-B | The quinoline of conditioning agent and related analogs as silent message regulatory factor | 西特里斯药业公司 | 2016-11-09 | — | — | CN | disclosed |
| US-20160310415-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160296523-A1 | Sirtuin Modulators as Inhibitors of Cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY | 2016-10-13 | — | — | US | disclosed |
| CN-106029789-A | Anthocyanidin complex | 赛博尔泰克股份公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9427472-B2 | Controlled release compositions for modulating free-radical induced damage and methods of use thereof | OTONOMY, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160201063-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160199446-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-14 | — | — | US | disclosed |
| EP-2479269-B1 | PERILLA FRUTESCENS VAR. CRISPA-ORIGIN PROMOTER FUNCTIONING IN PETAL | SUNTORY HOLDINGS LTD (JP) | 2016-07-13 | — | — | EP | disclosed |
| EP-3033423-A1 | EPIGENETIC REGULATORS OF FRATAXIN | Rana Therapeutics Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20160160263-A1 | PERSONALIZED PROTEASE ASSAY TO MEASURE PROTEASE ACTIVITY IN NEOPLASMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-09 | — | — | US | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9353154-B2 | Compositions for labeling nerves and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| WO-2016081692-A2 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079711-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079712-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079709-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079710-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-3017821-A1 | COMPOSITION HAVING A FUNCTION FOR ALLEVIATING PREMENSTRUAL SYNDROME AND MENSTRUAL PAIN | Amorepacific Corporation (KR) | 2016-05-11 | — | — | EP | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2768834-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9321797-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
| EP-2997029-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2993236-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | Glaxosmithkline LLC (US) | 2016-03-09 | — | — | EP | disclosed |
| CN-105392788-A | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2016-03-09 | — | — | CN | disclosed |
| CN-105358157-A | Beverage and its use | HYGIA PHARMACEUTICALS LLC | 2016-02-24 | — | — | CN | disclosed |
| CN-105339371-A | Thieno[3,2-d]pyrimidine-6-carboxamides and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2016-02-17 | — | — | CN | disclosed |
| US-20160030455-A1 | Drink Product and Use Thereof | HYGIA PHARMACEUTICALS, LLC | 2016-02-04 | — | — | US | disclosed |
| EP-2964654-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| CN-105198872-A | Chromenone analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2015-12-30 | — | — | CN | disclosed |
| US-20150359902-A1 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARLY RELEASABLE PRODRUG | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
| WO-2015186114-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| US-20150353604-A1 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2015-12-10 | — | — | US | disclosed |
| US-20150352100-A1 | USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS | AVANT DERMA PTE. LTD. (SG) | 2015-12-10 | — | — | US | disclosed |
| WO-2015186068-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| EP-2945627-A1 | USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS | Avant Derma PTE. Ltd. (SG) | 2015-11-25 | — | — | EP | disclosed |
| CN-102985553-B | Sirtuin activator and activation determination | SIRTRIS PHARMACEUTICALS, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-20150328336-A1 | DELPHINIDIN FOR COMBATING MELANOMA CELLS | SAPIOTEC GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20150320719-A1 | DELPHINIDIN FOR COMBATING MELANOMA CELLS | SAPIOTEC GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| US-20150306247-A1 | DELPHINIDIN COMPLEX AS AN ANTIPHLOGISTIC OR IMMUNOSUPPRESSIVE ACTIVE INGREDIENT | SAPIOTEC GMBH (DE) | 2015-10-29 | — | — | US | disclosed |
| CN-104940126-A | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTONOMY INC | 2015-09-30 | — | — | CN | disclosed |
| US-20150258202-A1 | ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA | SAPIOTEC GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| CN-102227417-B | Chromenone analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2015-09-16 | — | — | CN | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1774319-B1 | METHOD FOR ANALYZING OLIGOMERIC PROANTHOCYANIDIN (OPC) | SUNTORY HOLDINGS LTD (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150192564-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-9072773-B2 | Compositions for labeling nerves and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | GLAXOSMITHKLINE LLC (US) | 2015-06-25 | — | — | US | disclosed |
| CN-102227420-B | Quinazolinone, quinolone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2015-06-24 | — | — | CN | disclosed |
| EP-2376502-B1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| CN-102105133-B | Controlled release otic structure modulating and innate immune system modulating compositions and methods of treating otic disorders | OTONOMY INC | 2015-06-17 | — | — | CN | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | disclosed |
| CN-104491864-A | Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders | OTONOMY INC | 2015-04-08 | — | — | CN | disclosed |
| US-9000147-B2 | Nicotyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087822-A1 | ANTHOCYANIDIN COMPLEX | SAPIOTEC GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| WO-2014120837-A9 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARY RELEASEABLE PRODRUG | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-26 | — | — | WO | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-20150072950-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2015-03-12 | — | — | US | disclosed |
| EP-2841109-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | Ascendis Pharma A/S (DK) | 2015-03-04 | — | — | EP | disclosed |
| CN-102388054-B | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2015-03-04 | — | — | CN | disclosed |
| CN-104394869-A | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-04 | — | — | CN | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2167510-B1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2015023938-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20150051273-A1 | USE OF DELPHINIDIN AGAINST STAPHYLOCOCCUS AUREUS | SAPIOTEC GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| CN-104302673-A | Anthocyanidin complex | SAPIOTEC GMBH | 2015-01-21 | — | — | CN | disclosed |
| CN-104302183-A | Use of delphinidin against staphylococcus aureus | SAPIOTEC GMBH | 2015-01-21 | — | — | CN | disclosed |
| CN-104193740-A | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC | 2014-12-10 | — | — | CN | disclosed |
| CN-102014957-B | Otic formulations for the treatment of otic diseases and conditions | OTONOMY INC | 2014-12-10 | — | — | CN | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| EP-2805719-A1 | Nicotinamide riboside and analogues thereof | Glaxosmithkline LLC (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014186313-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | WO | disclosed |
| WO-2013059587-A9 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-8846947-B2 | Benzimidazoles and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846724-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140288052-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140274966-A1 | Drink Product Containing Genistein and Use Thereof | HYGIA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274965-A1 | Drink Product and Use Thereof | HYGIA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014138562-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140249147-A1 | Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators | GlaxoSmithKline, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140243425-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2768509-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2768833-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2768834-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| CN-104011053-A | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2014-08-27 | — | — | CN | disclosed |
| CN-103998451-A | Substituted bicyclic azaheterocyclic compounds and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2014-08-20 | — | — | CN | disclosed |
| CN-102143957-B | Benzimidazoles and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2014-08-20 | — | — | CN | disclosed |
| WO-2014120837-A2 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARY RELEASEABLE PRODRUG | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-2342188-B1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2344475-B1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2014112955-A1 | USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS | BIGLIARDI PAUL (SG) | 2014-07-24 | — | — | WO | disclosed |
| US-8784870-B2 | Controlled release compositions for modulating free-radical induced damage and methods of use thereof | OTONOMY, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| CN-103833775-A | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS INC | 2014-06-04 | — | — | CN | disclosed |
| US-20140088184-A1 | Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus | INSTITUT PASTEUR DE LILLE (FR) | 2014-03-27 | — | — | US | disclosed |
| CN-102421896-B | Perilla-derived promoter that functions in petals | SUNTORY HOLDINGS LTD | 2014-03-19 | — | — | CN | disclosed |
| EP-2119776-B1 | DAYFLOWER FLAVONOID 3',5'-HYDROXYLASE GENE | ISHIHARA SANGYO KAISHA (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8658779-B2 | Perilla-derived promoter functioning in petals | SUNTORY HOLDINGS LIMITED (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20130338178-A1 | SIRTUIN MODULATORS AS INHIBITORS OF CYTOMEGALOVIRUS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2670404-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | The Trustees of Princeton University (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2013160340-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-10-31 | — | — | WO | disclosed |
| US-20130289061-A1 | METHODS AND COMPOSITIONS TO PREVENT ADDICTION | THE GENERAL HOSPITAL CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20130252236-A1 | TUMOR STEM CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130202537-A1 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE | AVELAS BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130190309-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2013-07-25 | — | — | US | disclosed |
| EP-1910385-B1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2611822-A2 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE | Avelas Biosciences, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8440879-B2 | Flavonoid-3′,5′-hydroxylase gene of commelina communis | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| WO-2013059589-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059594-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059587-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130102009-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | GLAXOSMITHKLINE LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130096142-A1 | METHODS FOR HEALTHY AGING | SCRIPPS HEALTH (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-8410335-B2 | Method for producing rose with altered petal colors | SUNTORY HOLDINGS LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| CN-102985553-A | Sirtuin activators and activation assays | SIRTRIS PHARMACEUTICALS INC | 2013-03-20 | — | — | CN | disclosed |
| US-8383413-B2 | Method for analyzing oligomeric proanthocyanidin (OPC) | SUNTORY HOLDINGS LIMITED (JP) | 2013-02-26 | — | — | US | disclosed |
| EP-2558589-A2 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | Sirtris Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-1910362-B9 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-02-20 | — | — | EP | disclosed |
| CN-101874031-B | Sirtuin-modulating imidazothiazole compounds | SIRTRIS PHARMACEUTICALS INC | 2013-02-20 | — | — | CN | disclosed |
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| CN-101426481-B | Use of opioid receptor antagonists | DSM IP ASSETS BV | 2012-12-05 | — | — | CN | disclosed |
| US-20120302590-A1 | METHODS AND COMPOSITIONS TO PREVENT ADDICTION | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1910362-B1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1910384-B1 | IMIDAZO [2,1-B]THIAZOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-102725291-A | Bicyclic pyridines and analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2012-10-10 | — | — | CN | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| US-8268862-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2493888-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8242171-B2 | Method for reducing the weight of a subject or inhibiting weight gain in a subject | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-14 | — | — | US | disclosed |
| WO-2012106509-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2479269-A1 | PERILLA FRUTESCENS VAR. CRISPA-ORIGIN PROMOTER FUNCTIONING IN PETAL | Suntory Holdings Limited (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120165330-A1 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120148499-A1 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120134922-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20120134931-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2454271-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120108585-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| CN-102421896-A | Perilla-derived promoter that functions in petals | INT FLOWER DEV PTY LTD | 2012-04-18 | — | — | CN | disclosed |
| CN-102414180-A | 8-substituted quinolines and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2012-04-11 | — | — | CN | disclosed |
| EP-2429565-A2 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES | The Regents of the University of California (US) | 2012-03-21 | — | — | EP | disclosed |
| CN-102388054-A | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2012-03-21 | — | — | CN | disclosed |
| WO-2012031250-A2 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE | AVELAS BIOSCIENCES, NC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120042421-A1 | PERILLA-DERIVED PROMOTER FUNCTIONING IN PETALS | SUNTORY HOLDINGS LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| CN-102317284-A | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | SIRTRIS PHARMACEUTICALS INC | 2012-01-11 | — | — | CN | disclosed |
| CN-102307871-A | Isoindolinone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2012-01-04 | — | — | CN | disclosed |
| US-20110321184-A1 | PLANT WITH ALTERED INFLORESCENCE | SUNTORY HOLDINGS LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| CN-102272119-A | Pyridines, bicyclic pyridines and related analogs as sirtuin modulators | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110294833-A1 | Methods for Healthy Aging | SCRIPPS HEALTH (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110293525-A1 | TUMOR STEM CELLS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-12-01 | — | — | US | disclosed |
| CN-102227420-A | Quinazolinone, quinolone and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-10-26 | — | — | CN | disclosed |
| CN-102227417-A | Chromenone analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-10-26 | — | — | CN | disclosed |
| EP-1652916-B1 | PROCESS FOR PRODUCING ROSE WITH MODIFIED COLOR | SUNTORY HOLDINGS LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| CN-102177157-A | Benzoxazoles, benzothiazoles, and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| EP-2358870-A1 | A PLANT WITH ALTERED INFLORESCENCE | Suntory Holdings Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20110191907-A1 | FLAVONOID-3',5'-HYDROXYLASE GENE OF COMMELINA COMMUNIS | ISHIHARA SANGYO KAISHA LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| CN-102143957-A | Benzimidazoles and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-08-03 | — | — | CN | disclosed |
| WO-2011089214-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| CN-102112475-A | Imidazopyridine and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-06-29 | — | — | CN | disclosed |
| CN-102105133-A | Controlled release otic structure modulating and innate immune system modulating compositions and methods of treating otic disorders | OTONOMY INC | 2011-06-22 | — | — | CN | disclosed |
| CN-102083438-A | Quenolines and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-06-01 | — | — | CN | disclosed |
| US-20110126320-A1 | Method for producing rose with altered petal colors | SUNTORY HOLDINGS LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2306975-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | Otonomy, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| CN-102014957-A | Otic formulations for the treatment of otic diseases and conditions | OTONOMY INC | 2011-04-13 | — | — | CN | disclosed |
| EP-2296632-A2 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | Otonomy, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2011008992-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| US-7855289-B2 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100316679-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101918371-A | Amide derivatives as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2010-12-15 | — | — | CN | disclosed |
| CN-101910184-A | Solubility thiazole and pyridine | SIRTRIS PHARMACEUTICALS INC | 2010-12-08 | — | — | CN | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| CN-101874031-A | Sirtuin-modulating imidazothiazole compounds | SIRTRIS PHARMACEUTICALS INC | 2010-10-27 | — | — | CN | disclosed |
| WO-2010121023-A2 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010101949-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-19 | — | — | US | disclosed |
| EP-2217606-A1 | SOLUBILIZED THIAZOLOPYRIDINES | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-101482500-B | Fast detection method for dihydro flavanol 4-reductase/leucocyanidin reductase in tree plant | UNIV ANHUI AGRICULTURE | 2010-08-18 | — | — | CN | disclosed |
| EP-2215066-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| CN-101801981-A | Sirtuin-modulating thiazolopyridine compounds | SIRTRIS PHARMACEUTICALS INC | 2010-08-11 | — | — | CN | disclosed |
| WO-2010088574-A1 | AZABENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| CN-101778576-A | stabilized anthocyanin compositions | OMNICA GMBH | 2010-07-14 | — | — | CN | disclosed |
| WO-2010077947-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077686-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| WO-2010071853-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069004-A1 | A PLANT WITH ALTERED INFLORESCENCE | INTERNATIONAL FLOWER DEVELOPMENTS PTY LTD (AU) | 2010-06-24 | — | — | WO | disclosed |
| CN-1836039-B | Process for producing rose with modified color | INTERNAT FLOWER DEV PTY LTD | 2010-05-26 | — | — | CN | disclosed |
| WO-2010056549-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-7709701-B2 | Genetic manipulation of condensed tannins | THE SAMUEL ROBERTS NOBLE FOUNDATION (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2170905-A2 | SIRTUIN MODULATING THIAZOLOPYRIDINE COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081159-A1 | Profiling reactive oxygen, nitrogen and halogen species | ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. | 2010-04-01 | — | — | US | disclosed |
| EP-2167510-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7682637-B2 | Efficient method for producing compositions enriched in total phenols | PHENOLICS, LLC (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2010019606-A1 | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2010011605-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2010008995-A2 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090325857-A1 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | disclosed |
| WO-2009158646-A1 | THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009146358-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7622638-B2 | Comprises nucleotide sequences coding dihydroflavonol reductase (DFR) for generating transgenic plants with increased carbohydrates and nutritional value and which drecrease bloating in animals | THE SAMUEL ROBERTS NOBLE FOUNDATION (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2119776-A1 | DAYFLOWER FLAVONOID 3',5'-HYDROXYLASE GENE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| EP-1572219-A4 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN TOTAL PHENOLS | PHENOLICS LLC (US) | 2009-07-29 | — | — | EP | disclosed |
| CN-101482500-A | Fast detection method for dihydro flavanol 4-reductase/leucocyanidin reductase in tree plant | UNIV ANHUI AGRICULTURE (CN) | 2009-07-15 | — | — | CN | disclosed |
| US-20090163476-A1 | N-Phenyl Benzamide Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009058348-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| CN-101426481-A | Use of opioid receptor antagonists | DSM IP ASSETS BV (NL) | 2009-05-06 | — | — | CN | disclosed |
| US-20090105246-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090099373-A1 | COMPOSITIONS ENRICHED IN ANTHOCYANINS | PHENOLICS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009049018-A1 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2034977-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090041687-A1 | Use of opioid receptor antagonists | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| CN-101360421-A | Nicotinoyl riboside compositions and methods of use | CORNELL RES FOUNDATION INC (US) | 2009-02-04 | — | — | CN | disclosed |
| WO-2009014674-A1 | HETEROCYCLYLAMIDES AS GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015180-A2 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015179-A1 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090004311-A1 | SKIN-WHITENING AGENT CONTAINING POLYPHENOL COMPOUND | NICHIREI FOODS, INC. (JP) | 2009-01-01 | — | — | US | disclosed |
| WO-2008156866-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156869-A2 | SIRTUIN MODULATING THIAZOLOPYRIDINE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080311662-A1 | Method for Analyzing Oligomeric Proanthocyanidin (Opc) | SUNTORY HOLDINGS LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7462370-B2 | Compositions enriched in anthocyanins | PHENOLICS, LLC (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| CN-101282761-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| WO-2008119070-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-10-02 | — | — | WO | disclosed |
| CN-101272787-A | Use of opioid receptor antagonists | DSM IP ASSETS BV (NL) | 2008-09-24 | — | — | CN | disclosed |
| US-20080207770-A1 | COMPOSITIONS ENRICHED IN PHENOLIC COMPOUNDS AND METHODS FOR PRODUCING THE SAME | PHENOLICS, LLC (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080199548-A1 | Efficient method for producing compositions enriched in total phenols | PHENOLICS, LLC (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1957109-A2 | MODULATORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF | Sirtris Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1957086-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1546335-B1 | GENETIC MANIPULATION OF CONDENSED TANNINS | SAMUEL ROBERTS NOBLE FOUND INC (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008089439-A2 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008082646-A2 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008073451-A2 | BENZOIMIDAZOLE DERIVATIVES AS SIRTUIN (SIR) MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1928440-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1926490-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2008-06-04 | — | — | EP | disclosed |
| EP-1912632-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910384-A1 | IMIDAZO [2,1-B]THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910385-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910380-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910362-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2008021048-A2 | ADP-RIBOSYLTRANSFERASE BASED METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1877054-A2 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | Sirtris Pharmaceuticals, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1863462-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7306815-B2 | Compositions enriched in phenolic compounds and methods for producing the same | PHENOLICS, LLC (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070269536-A1 | COMPOSITIONS ENRICHED IN ANTHOCYANINS | PHENOLICS, LLC (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1856099-A2 | ACRIDINE AND QUINOLINE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1853610-A1 | N-PHENYL BENZAMIDE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1853590-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1850840-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007121916-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-11-01 | — | — | WO | disclosed |
| US-20070248590-A1 | Modulators of CDC2-like kinases (CLKS) and methods of use thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007102861-A2 | MODULATORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070189997-A1 | Skin-whitening agent containing polyphenol compound | NICHIREI FOODS INC. (JP) | 2007-08-16 | — | — | US | disclosed |
| WO-2007061798-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | CORNELL RESEARCH FOUNDATION INC. | 2007-05-24 | — | — | US | disclosed |
| EP-1787624-A1 | SKIN-LIGHTENING AGENT CONTAINING POLYPHENOL COMPOUND | Nichirei Foods Inc. (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-7211413-B2 | Process for producing purified anthocyanin and crystalline anthocyanin | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| EP-1774319-A1 | METHOD FOR ANALYZING OLIGOMERIC PROANTHOCYANIDIN (OPC) | SUNTORY LIMITED (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007039058-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | disclosed |
| EP-1766031-A2 | GENETIC MANIPULATION OF CONDENSED TANNINS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765316-A2 | METHODS AND COMPOSITIONS FOR MODULATING BAX-KU70-MEDIATED APOPTOSIS | The President and Fellows of Harvard College (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007005453-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060292099-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-20060280816-A1 | Efficient method for producing compositions enriched in total phenols | PHENOLICS, LLC (US) | 2006-12-14 | — | — | US | disclosed |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006127987-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1718319-A1 | COMPOSITIONS ENRICHED IN PHENOLIC COMPOUNDS AND METHODS FOR PRODUCING THE SAME | Phenolics, LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20060229265-A1 | Nicotinamide riboside and analogues thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006105440-A2 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006105403-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1836039-A | Process for producing rose with modified color | INTERNAT FLOWER DEV PTY LTD (AU) | 2006-09-20 | — | — | CN | disclosed |
| WO-2006094210-A2 | TETRAHYDROQUINOXALINONE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094236-A1 | N-PHENYL BENZAMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094233-A1 | N,N'-DICYCLIC ISOTHIOUREA SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094248-A1 | ARYL-SUBSTITUTED CYCLIC SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094246-A2 | N-ARYLMETHYL BENZAMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094237-A2 | ACRIDINE AND QUINOLINE DERVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094235-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094209-A2 | N-BENZIMIDAZOLYLALKYL-SUBSTITUTED AMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060166330-A1 | Process for producing purified anthocyanin and crystalline anthocyanin | BIOSCIENCE LABS (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2006076681-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060123508-A1 | Genetic manipulation of condensed tannins | SAMUEL ROBERTS NOBEL FOUNDATION | 2006-06-08 | — | — | US | disclosed |
| EP-1328282-B1 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS | PHENOLICS LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-25 | — | — | US | disclosed |
| EP-1652916-A1 | PROCESS FOR PRODUCING ROSE WITH MODIFIED COLOR | INTERNATIONAL FLOWER DEVELOPMENTS Proprietary Limited (AU) | 2006-05-03 | — | — | EP | disclosed |
| US-20060084085-A1 | Methods and compositions for modulating Bax-mediated apoptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-04-20 | — | — | US | disclosed |
| US-20060073220-A1 | Cinnamon extract enriched for polyphenols and methods of preparing same | PHENOLICS, LLC | 2006-04-06 | — | — | US | disclosed |
| WO-2006014499-A1 | CINNAMON EXTRACT ENRICHED FOR POLYPHENOLS AND METHODS OF PREPARING SAME | PHENOLICS, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006011640-A1 | METHOD FOR ANALYZING OLIGOMERIC PROANTHOCYANIDIN (OPC) | SUNTORY LIMITED (JP) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010096-A2 | GENETIC MANIPULATION OF CONDENSED TANNINS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006007411-A2 | METHODS AND COMPOSITIONS FOR MODULATING BAX-MEDIATED APOPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20050266104-A1 | Efficient method for producing compositions enriched in total phenols | PHENOLICS, LLC | 2005-12-01 | — | — | US | disclosed |
| EP-1318201-B1 | PROCESS FOR PRODUCING PURIFIED ANTHOCYANIN AND CRYSTALLINE ANTHOCYANIN | MEIJI SEIKA KAISHA (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-6960360-B2 | Efficient method for producing compositions enriched in total phenols | PHENOLICS, LLC (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1572219-A1 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN TOTAL PHENOLS | Phenolics, LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1546335-A4 | GENETIC MANIPULATION OF CONDENSED TANNINS | SAMUEL ROBERTS NOBLE FOUND INC (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005072762-A1 | COMPOSITIONS ENRICHED IN PHENOLIC COMPOUNDS AND METHODS FOR PRODUCING THE SAME | PHENOLICS, LLC (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1546335-A2 | GENETIC MANIPULATION OF CONDENSED TANNINS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050037095-A1 | Compositions enriched in anthocyanins | PHENOLICS, LLC | 2005-02-17 | — | — | US | disclosed |
| US-20050010040-A1 | Compositions enriched in phenolic compounds and methods for producing the same | PHENOLICS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-6780442-B2 | PURIFICATION STEP USING A BROMINATED POLYSTYRENE RESIN TO ADSORB ANTHOCYANINS | HAUSER, INC. | 2004-08-24 | — | — | US | disclosed |
| WO-2004047847-A1 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN TOTAL PHENOLS | PHENOLICS, LLC (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040101933-A1 | Process for producing purified anthocyanin and crystalline anthocyanin | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| US-20040093632-A1 | Genetic manipulation of condensed tannins | THE SAMUEL ROBERTS NOBEL FOUNDATION | 2004-05-13 | — | — | US | disclosed |
| EP-1328282-A4 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS | HAUSER INC (US) | 2004-02-11 | — | — | EP | disclosed |
| WO-2004002215-A2 | GENETIC MANIPULATION OF CONDENSED TANNINS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030149252-A1 | Efficient method for producing compositions enriched in total phenols | PHENOLICS, LLC | 2003-08-07 | — | — | US | disclosed |
| EP-1328282-A1 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS | Hauser, Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1318201-A1 | PROCESS FOR PRODUCING PURIFIED ANTHOCYANIN AND CRYSTALLINE ANTHOCYANIN | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-20020055471-A1 | Efficient method for producing compositions enriched in anthocyanins | PHENOLICS, LLC | 2002-05-09 | — | — | US | disclosed |
| WO-2002017732-A2 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS | TEMPESTA, MICHAEL, S. | 2002-03-07 | — | — | WO | disclosed |
| WO-2002017945-A1 | EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS | HAUSER, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-20010009716-A1 | MICROPOROUS STRUCTURES AND PROCESS FOR PRODUCING THE SAME | INOAC TECHNICAL CENTER CO., LTD. (JP) | 2001-07-26 | — | — | US | disclosed |
| US-6159585-A | Security paper | GEORGIA-PACIFIC CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| WO-1999021006-A9 | PHARMACEUTICAL GRADE VALERIAN, BLACK COHOSH, VITEX AGNUS-CASTUS, BILBERRY AND MILK THISTLE | PHARMAPRINT INC (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999021006-A1 | PHARMACEUTICAL GRADE VALERIAN, BLACK COHOSH, VITEX AGNUS-CASTUS, BILBERRY AND MILK THISTLE | PHARMAPRINT, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998041688-A1 | SECURITY PAPER | GEORGIA-PACIFIC CORPORATION, INC. (US) | 1998-09-24 | — | — | WO | disclosed |
| EP-0390496-B1 | Intermediates useful for the synthesis of delphinidin chloride | IDB HOLDING SPA (IT) | 1994-11-30 | — | — | EP | disclosed |
| EP-0390496-B1 | Intermediates useful for the synthesis of delphinidin chloride | IDB HOLDING SPA (IT) | 1994-11-30 | — | — | EP | disclosed |
| EP-0490615-A1 | Process for synthesising anthocyanidins | IDB HOLDING S.p.A. (IT) | 1992-06-17 | — | — | EP | disclosed |
| US-5070212-A | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF DELPHINIDIN CHLORIDE | IDB HOLDING SPA (IT) | 1991-12-03 | — | — | US | disclosed |
| US-5070212-A | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF DELPHINIDIN CHLORIDE | IDB HOLDING SPA (IT) | 1991-12-03 | — | — | US | disclosed |
| JP-H03209321-A | ANTI-RETROVIRUS AGENT | TORAY IND INC | 1991-09-12 | — | — | JP | disclosed |
| JP-H02289562-A | INTERMEDIATE USEFUL FOR SYNTHESIS OF DELPHINIDIN CHLORIDE | IDB HOLDING SPA | 1990-11-29 | — | — | JP | disclosed |
| EP-0390496-A1 | Intermediates useful for the synthesis of delphinidin chloride | IDB HOLDING S.p.A. (IT) | 1990-10-03 | — | — | EP | disclosed |
| EP-0390496-A1 | Intermediates useful for the synthesis of delphinidin chloride | IDB HOLDING S.p.A. (IT) | 1990-10-03 | — | — | EP | disclosed |
| EP-0074505-B1 | FERTILITY INDICATOR SYSTEM | Goldman, Dorothee, F.E. (US) | 1986-11-12 | — | — | EP | disclosed |
| WO-1983001117-A1 | FERTILITY INDICATOR SYSTEM CONTAINING ANTHOCYANIN PIGMENT | GOLDMAN, DOROTHEE, F., E. | 1983-03-31 | — | — | WO | disclosed |
| EP-0074505-A2 | Fertility indicator system | Goldman, Dorothee, F.E. (US) | 1983-03-23 | — | — | EP | disclosed |
| US-4358288-A | Fertility indicator system containing anthocyanin pigment | GOLDMAN, DOROTHEE F.E. | 1982-11-09 | — | — | US | disclosed |
| US-4358288-A | Fertility indicator system containing anthocyanin pigment | GOLDMAN, DOROTHEE F.E. | 1982-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | EGFR 1868/4885KDR 927/4885DPP4 3841/4885 |
| US-20210008028-A1 | COMPOSITIONS AND METHODS FOR TREATING DIARRHEAL DISEASES | SI, SCD, MB | EGFR 4766/4885KDR 3372/4885DPP4 1623/4885 |
| US-10092580-B2 | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTC, TLR3, STING1 | EGFR 1547/4885KDR 604/4885DPP4 3190/4885 |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | FABP4, PLIN1, SIRT1 | EGFR 4664/4885KDR 3976/4885DPP4 220/4885 |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | AGER, CKMT1A; CKMT1B, GLA | EGFR 1153/4885KDR 3861/4885DPP4 619/4885 |
| US-10342836-B2 | Composition having a function for alleviating premenstrual syndrome and menstrual pain | GRK5, GRM5, GRM6 | EGFR 4770/4885KDR 4479/4885DPP4 4397/4885 |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | EGFR 4546/4885KDR 4064/4885DPP4 201/4885 |
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, NAMPT, NAPRT | EGFR 2286/4885KDR 3817/4885DPP4 3535/4885 |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | DNPEP, FOLH1, CTSL | EGFR 324/4885KDR 2205/4885DPP4 758/4885 |
| US-20140243425-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | EGFR 2423/4885KDR 922/4885DPP4 3309/4885 |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | SIRT1, SIRT2, SIRT7 | EGFR 4051/4885KDR 1727/4885DPP4 2670/4885 |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | EGFR 2423/4885KDR 922/4885DPP4 3309/4885 |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | EGFR 3640/4885KDR 4267/4885DPP4 3642/4885 |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | EGFR 3879/4885KDR 4073/4885DPP4 2154/4885 |
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | CTSL, SLC16A7, SLC16A8 | EGFR 1635/4885KDR 843/4885DPP4 110/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | EGFR 4219/4885KDR 4304/4885DPP4 2164/4885 |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | EGFR 4451/4885KDR 1402/4885DPP4 1525/4885 |
| US-20160296523-A1 | Sirtuin Modulators as Inhibitors of Cytomegalovirus | SIRT1, SIRT2, SIRT7 | EGFR 4051/4885KDR 1727/4885DPP4 2670/4885 |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | EGFR 2366/4885KDR 171/4885DPP4 2682/4885 |
| US-20210030713-A1 | ANTHOCYANIDIN COMPLEX | DNMT1, DNMT3B, ERG28 | EGFR 4192/4885KDR 3636/4885DPP4 1005/4885 |
| US-20150051273-A1 | USE OF DELPHINIDIN AGAINST STAPHYLOCOCCUS AUREUS | NISCH, SPAST, CUTA | EGFR 1194/4885KDR 4606/4885DPP4 208/4885 |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | SIRT1, SIRT2, SIRT3 | EGFR 4484/4885KDR 3592/4885DPP4 3232/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | EGFR 4451/4885KDR 1402/4885DPP4 1525/4885 |
| US-20140288052-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EGFR 4192/4885KDR 1197/4885DPP4 1432/4885 |
| US-20130096142-A1 | METHODS FOR HEALTHY AGING | HTT, TELO2, GLA | EGFR 4821/4885KDR 4659/4885DPP4 2714/4885 |
| US-20170014377-A1 | ANTHOCYANIDIN COMPLEX | DNMT1, DNMT3B, ERG28 | EGFR 4192/4885KDR 3636/4885DPP4 1005/4885 |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EGFR 3708/4885KDR 1526/4885DPP4 1780/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | EGFR 4585/4885KDR 645/4885DPP4 1992/4885 |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EGFR 3224/4885KDR 1697/4885DPP4 1559/4885 |
| US-20150352100-A1 | USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS | OPRD1, OPRL1, OPRK1 | EGFR 319/4885KDR 498/4885DPP4 3600/4885 |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | EGFR 1314/4885KDR 1494/4885DPP4 1907/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | EGFR 1314/4885KDR 1494/4885DPP4 1907/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | EGFR 3668/4885KDR 3309/4885DPP4 3217/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | EGFR 1314/4885KDR 1494/4885DPP4 1907/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EGFR 3012/4885KDR 1659/4885DPP4 2284/4885 |
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | EGFR 2978/4885KDR 1598/4885DPP4 2237/4885 |
| US-11744820-B2 | Inhibitors of microbially induced amyloid | APP, PSEN1, BACE1 | EGFR 4818/4885KDR 4882/4885DPP4 1362/4885 |
| US-20160310415-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | EGFR 2423/4885KDR 922/4885DPP4 3309/4885 |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | EGFR 1314/4885KDR 1494/4885DPP4 1907/4885 |
| US-20200306252-A1 | COMPOSITION FOR PREVENTING AND/OR TREATING DEMENTIA | PSEN2, PSEN1, APP | EGFR 4621/4885KDR 4672/4885DPP4 1183/4885 |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | EGFR 1314/4885KDR 1494/4885DPP4 1907/4885 |
| US-20090105246-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | EGFR 4451/4885KDR 1402/4885DPP4 1525/4885 |
| US-10596259-B2 | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof | AURKA, AURKB, MMAB | EGFR 280/4885KDR 2127/4885DPP4 4122/4885 |
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EGFR 2978/4885KDR 1598/4885DPP4 2237/4885 |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EGFR 3708/4885KDR 1526/4885DPP4 1780/4885 |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | EGFR 3640/4885KDR 4267/4885DPP4 3642/4885 |
| US-20160199446-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | EGFR 1868/4885KDR 927/4885DPP4 3841/4885 |
| US-12630776-B2 | Fuel additive composition | AAAS, AADAT, SLC6A19 | EGFR 1932/4885KDR 772/4885DPP4 2740/4885 |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | EGFR 4856/4885KDR 4003/4885DPP4 1576/4885 |
| US-20190192542-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | EGFR 3640/4885KDR 4267/4885DPP4 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.